Blog-Featured

VERO Biotech Secures $50 Million Funding from Runway Growth Capital

A senior secured term loan will support the further development…
Read more
Blog-Featured

FDA Approves Interhospital Patient Transport Use of VERO Biotech’s GENOSYL® Delivery System, Resulting in the Broadest Label in the Inhaled Nitric Oxide Space

The GENOSYL® DS facilitates patient treatment in interhospital…
Read more
Blog-Featured

Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine

Clinicians report on first at-home treatment of COVID-19 patient…
Read more
Blog-Featured

VERO Biotech Commits to Atlanta Healthcare Providers, Patients and Workforce During COVID-19 Pandemic

Atlanta-based biotech provides innovative portable inhaled nitric…
Read more
Blog-Featured

FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

Read more
Blog-Featured

VERO Biotech Announces First Patient With COVID-19 Infection Complicating Pulmonary Hypertension Treated with GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

Treatment informs FDA approval for emergency expanded access…
Read more
Blog-Featured

VERO Biotech, Leaders in the Development of Innovative Technologies for Inhaled Nitric Oxide Delivery, to Present at Biotech Showcase 2020

Prestigious investor conference runs concurrently with 38th Annual…
Read more
Blog-Featured

AARC 2018

We will be attending the 2018 AARC Congress in Las Vegas on…
Read more